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Abstract 12 
A number of drugs have been used to treat asphyxia in newborn calves and the aim of the 13 
current study was to investigate the effect of commonly-used stimulant drugs on ventilation, 14 
arterial blood gas and acid base variables. A group (n=18) of newborn (3 – 15 h-old) calves were 15 
treated in a randomised sequence with doxapram (40 mg, IV), lobeline (5 mg, IV) or prethcamide 16 
(5 mL, consisting of 375 mg crotethamide and 375 mg cropropamide, buccally). Blood and 17 
spirometric measurements, using an ultrasonic spirometer, were collected prior to and 1, 5, 15, 18 
30, 60, 90 min after administration of each drug. Doxapram caused a significant increase in the 19 
respiratory rate, peak inspiratory and expiratory flow and minute volume (Vmin) during the 90-20 
min post treatment study period, although maximum values occurred 1 min after treatment. The 21 
Vmin increased from 13.8 ± 5.0 L to 28.5 ± 12.3 L. Prethcamide, but not lobeline, also caused 22 
significant increases in inspiratory and expiratory volumes. The effects of doxapram on 23 
ventilation were accompanied by an increase in arterial partial pressure of oxygen (PaO2) (77.7 ± 24 
18.8 mmHg to 93.2 ± 23.7 mmHg), a decrease in arterial partial pressure of carbon dioxide 25 
(PaCO2) (42.6 ± 4.9 mmHg to 33.1 ± 6.6 mmHg), a significant increase in pH and a significant 26 
decrease in bicarbonate concentration and base excess at 1 min after treatment. Prethcamide 27 
caused a gradual increase in PaO2 and decrease in PaCO2 over 90 min, whereas lobeline had no 28 
measurable effect on the investigated variables. Of the three treatments, only doxapram had a 29 
distinct stimulatory effect on respiration in healthy neonatal calves and may therefore be useful to 30 
treat asphyxia in calves. 31 
 32 
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Introduction 35 
The high rate of perinatal calf mortality following dystocia is a significant problem in 36 
many countries (Meyer et al., 2001; Berglund et al., 2003; Steinbock et al., 2003) and has many 37 
different causes (Lombard et al., 2007; Mee, 2008b; Gulliksen et al., 2009; Gundelach et al., 38 
2009; Bleul, 2011). Critical factors are respiratory and metabolic acidosis, referred to as 39 
asphyxia, caused by hypoxia and hypercapnia (Szenci et al., 1988). Severe asphyxia can lead to 40 
impaired respiration or even apnoea and this is mainly attributable to depression of the 41 
respiratory centre (Daniel et al., 1966; Phillips et al., 2001). This depression can lead to a reduced 42 
respiratory drive and calves may fail to develop a normal respiratory pattern and hypoxia and 43 
hypercapnia are exacerbated. 44 
 45 
In an attempt to break this vicious circle, numerous respiratory stimulants have been used 46 
in a variety of species, including human babies (Beretta et al., 1973; Gupta and Moore, 1973; 47 
Szenci, 1986; Bleul et al., 2010). The mechanisms of action of the various stimulants vary with 48 
the site of action, with some having a general stimulatory effect on the central nervous system, 49 
while others stimulate chemoreceptors in the carotid artery or aortic bodies. The site of action 50 
may be dose-related (Plumb, 2005). The most commonly used respiratory stimulants in 51 
veterinary medicine are doxapram, lobeline and prethcamide (Kochli, 1969; Szenci, 1986; 52 
Herfen, 1997; Kersting, 1997; Richter, 2005; Giguere et al., 2008).  53 
 54 
Doxapram affects chemoreceptors of the carotid artery and aorta. This is mediated by 55 
potassium channels, which belong to the TASK K2P channels. However, doxapram also has a 56 
direct effect on the respiratory centre, but the mechanism of action is unknown (Yost, 2006). It 57 
was recently reported that glial cells are involved in the excitatory effects of doxapram on rat 58 
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brainstem slices in vitro (Li et al., 2010). In the healthy newborn calf, doxapram induces a 59 
distinct increase in respiratory rate (RR) and a decrease in PaCO2 in arterial blood (Bleul et al., 60 
2010). Lobeline acts on nicotinic receptors and its respiratory analeptic effect is mainly mediated 61 
by stimulating vegetative ganglia. In the adult horse, lobeline causes an increase in RR and 62 
decrease in PaCO2 (Marlin et al., 2000). Prethcamide is composed of a mixture of cropropamide 63 
and crotethamide and is believed to increase primarily the tidal volume via stimulation of the 64 
respiratory centre, whereas its effect on RR is minimal (Sams et al., 1997). The specific 65 
mechanism and site of action of prethcamide is unknown, although the effect of all three 66 
respiratory stimulants on ventilation is independent of the partial pressure of CO2 (Anderton and 67 
Harris, 1963; Nishino et al., 1982; van Lunteren et al., 1984). 68 
 69 
Although doxapram, lobeline and prethcamide are approved for use in neonatal calves in 70 
many countries, there is only limited information on their effect on venous and arterial blood gas 71 
variables (Szenci, 1986; Herfen, 1997; Bleul et al., 2010). The aim of the current study was to 72 
investigate if doxapram, lobeline and prethcamide would cause measurable changes in 73 
spirometric (using ultrasonic spirometry), pulmonary gas exchange (evaluated using blood gas 74 
analysis) and acid-base variables in healthy newborn calves. Any drug improving the indices of 75 
spontaneous breathing may therefore be to treat asphyxia in neonatal calves. 76 
 77 
Material and methods 78 
Animals 79 
Eighteen calves, consisting of 11 Swiss Braunvieh, 6 Holstein Frisian and 1 Swiss 80 
Braunvieh x Simmental calves, were used for the study. There were 12 heifer calves and six bull 81 
calves with a bodyweight (BW) of 45 ± 5 kg (mean ± SD) and were born after a gestation of 288 82 
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± 6 days. The calves underwent a clinical examination and venous blood gas analysis using a 83 
blood gas analyser (Rapidlab 248, Siemens). Results of clinical examination were normal and 84 
there were no signs of circulatory or pulmonary abnormalities. All the calves had a venous blood 85 
pH >7.2. At the beginning of the experiment the calves were between 3 - 15 h old. 86 
 87 
Catheters 88 
The placement sites for catheters were shaved and disinfected with alcohol. For collection 89 
of arterial blood, an 18 G indwelling catheter (Neolus) was placed in the medial intermediate 90 
branch of the caudal auricular artery and fastened with cyanoacrylate glue  in 12 calves. In the 91 
remaining six calves, access to this artery was not possible and a 22 G catheter (Neolus) was 92 
placed in a femoral artery after local administration of 2 mL lidocaine (Lidocain-Hyaluronidase 93 
2%, Streuli) and fixed in place with a suture. For the administration of drugs, a 14 G indwelling 94 
catheter was placed in a jugular vein after local administration of 2 mL lidocaine (Lidocain-95 
Hyaluronidase 2%, Streuli) and sutured in place. 96 
 97 
Administration of respiratory stimulants 98 
The study was a randomised three-way cross-over design, with each treatment 99 
administered at the end of a 15 min resting period. Calves were randomly assigned to receive 100 
either doxapram (40 mg, IV; Dopram-V, Albrecht), lobeline (5 mg, IV; Zoolobelin, Arovet) or 101 
prethcamide (5 mL, buccally, consisting of 375 mg crotethamide and 375 mg cropropamide; 102 
Respirot, Novartis). The drug doses were based on the manufacturer’s recommendations 103 
guidelines or from published studies (Beretta et al., 1973; Bureau et al., 1999a; Herfen and 104 
Bostedt, 1999; Bleul et al., 2005). Measurements were carried out for 90 min after administration, 105 
which was followed by a wash-out period of 2 h before the next drug was given. Another 2 h 106 
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wash-out period followed the 90 min measurement period, and then the third drug was given. The 107 
study design ensured that all three respiratory stimulants were administered in a random order to 108 
avoid potential confounding effects of the sequence of administration. 109 
 110 
Blood sampling 111 
Arterial blood samples for blood gas analysis were collected before administration 112 
(baseline) and arterial and venous blood samples 1, 5, 15, 30, 60 and 90 min after administration 113 
of the stimulant. Blood gas monovettes coated with calcium-balanced heparin to generate a 114 
concentration of 50 IU heparin/mL blood (Sarstedt) were used for blood gas analysis. PaO2 and 115 
PaCO2 and oxygen saturation (sO2) were measured either immediately after blood collection or 116 
within 30 min of collection, during which time the blood samples were stored on ice. The blood 117 
pH, bicarbonate concentration (HCO3
-
) and base excess (BE) were also measured using the blood 118 
gas analyser (Rapidlab 248, Siemens). This instrument uses three different sensors for measuring 119 
PaO2, PaCO2 and pH, which are corrected for body temperature of the calf. The remainder 120 
parameters were calculated by the blood gas analyser. 121 
 122 
Spirometry 123 
Heart and respiratory rates and body temperature were measured immediately before each 124 
blood collection, after which spirometric measurements were carried out using an 125 
ultrasonographic spirometer (Exhalyzer D, Eco Medics). The principle of ultrasonographic 126 
spirometry is based on the measurement of two transit times of ultrasonographic waves across a 127 
tubular sensor. Measurements were not affected by the composition, temperature and humidity of 128 
the air. Ultrasonic pulses were emitted from two transducers in opposite positions. The tubular 129 
spirette (respiratory tube) through which the calf breathes was positioned at an acute angle to the 130 
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ultrasonic pulses. Movement of air in the spirette results in changes of the transit time (time of 131 
flight) of the sound waves, which was used to calculate the velocity of air flow (Buess et al., 132 
1986). The spirometer was calibrated daily according to the manufacturer. An anaesthetic mask, 133 
equipped with a rubber collar, with an approximated equipment dead space of 1500 mL, as 134 
determined by water displacement, was used for the measurements (Fig. 1). The anterior opening 135 
of the mask was adapted to the size of the spirette such that the entire airflow passed through it.  136 
 137 
Once the standing calf was accustomed to the mask, which usually took 30 s to 1 min, 138 
measurements were carried out for a period of 1 min before the respiratory stimulant was 139 
administered. All other measurements were made after blood sampling 1, 5, 15, 30, 60 and 90 140 
min after administration of the stimulant. The spirometric data were transferred to a computer and 141 
analysed using a software program (Spiroware 3.0, Eco Medics). Based on the velocity of air 142 
flow, the volumes of inhaled and exhaled air were calculated, from which the following variables 143 
were derived. The volume measured during each inspiration and expiration was expressed for 144 
each breath as Vin (L) and Vexp (L). The minute volume (Vmin, L) was calculated using the 145 
formula (Vin + Vexp) x 0.5 x RR. Finally, the peak inspiratory flow (PIF, L/s) and peak expiratory 146 
flow (PEF, L/s) and the ratio of duration of expiration and duration of inspiration (Texp/Tin) were 147 
calculated. 148 
 149 
Statistical analysis 150 
The data were checked for normal distribution using the Shapiro-Wilk test and statistical 151 
analyses were performed using Stat View 5.0 (SAS Institute). All parameters were normally 152 
distributed, so results were given as mean ± standard deviation ( x  ± SD). To verify if the results 153 
were influenced by the sequence of administered stimulant, one-way ANOVA was used to 154 
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compare baseline values of the three treatment periods. Differences in the course over time of 155 
various variables within a treatment group and between respiratory stimulants were analysed 156 
using ANOVA for repeated measures. If ANOVA revealed no significant differences in the 157 
course over time of the variables, Fisher’s PLSD post-hoc test was used for comparison among 158 
stimulants at individual measuring times. In case ANOVA revealed statistical differences over 159 
time within a treatment group, paired t test was used for comparison among values at different 160 
time points. P-value ≤ 0.05 was considered significant. 161 
 162 
This study was approved (92/2008) by the Committee for the Permission of Animal 163 
Experimentation of the Canton of Zurich. 164 
 165 
Results 166 
Clinical signs indicative of adverse side effects of the respiratory stimulants were not 167 
observed in any of the calves during the study period. The anaesthetic mask was well tolerated 168 
and no disturbances of the spirometric measurements due to movements of the calves were 169 
observed. There were no significant differences in baseline values between treatment groups for 170 
any measured variables. The rectal temperature ranged from 38.3 - 38.8 °C and the heart rate 171 
from 109 - 129 beats/min; there were no significant changes over time in the latter variable. 172 
Within 1 min of doxapram administration, the RR increased from 69 ± 23 breaths/min to 105 ± 173 
33 breaths/min (P < 0.001; Fig. 2a). Lobeline and prethcamide had no significant effect on RR.  174 
 175 
Spirometry 176 
Lobeline and prethcamide had no effect on PIF and PEF, whereas doxapram led to an 177 
increase in both PIF and PEF (P < 0.001). The highest PIF value of 1.59 ± 0.69 L/s occurred 1 178 
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min after doxapram administration, and the measurements remained significantly higher than the 179 
baseline value of 0.79 ± 0.21 L/s for 60 min (Fig. 2b). Likewise, the PEF increased from the 180 
baseline value of 0.78 ± 0.24 L/s to a maximum of 1.44 ± 0.58 L/s 1 min after doxapram 181 
treatment and remained significantly increased for the entire study period of 90 min. 182 
 183 
The three treatments did not differ with respect to the time courses of Vin and Vexp. One 184 
min after treatment Vin was different between the doxapram and the lobeline group (P < 0.05). 185 
After treatment with doxapram, Vin and Vexp increased within 1 min from 0.28 ± 0.08 L - 0.33 ± 186 
0.06 L and from 0.21 ± 0.07 L - 0.27 ± 0.05 L, respectively (Vin P ≤ 0.05; Vexp P < 0.001). After 187 
treatment with prethcamide, Vin and Vexp increased within 1 min from 0.26 ± 0.08 L - 0.31 ± 0.10 188 
L and from 0.25 ± 0.10 L - 0.27 ± 0.10 L, respectively (Vin P ≤ 0.05; Vexp P ≤ 0.05). Lobeline did 189 
not affect Vin and Vexp. 190 
 191 
Doxapram differed significantly from prethcamide and lobeline with respect to the time 192 
course of Vmin (Fig. 2c; P < 0.001). After treatment with doxapram, Vmin increased within 1 min 193 
from 13.83 ± 5.00 L to a maximum value of 28.45 ± 12.31 L. The measurements decreased 194 
gradually, but remained significantly higher than the baseline value until the last measurement 90 195 
min after treatment. Prethcamide and lobeline did not affect Vmin. 196 
 197 
The ratio Texp/Tinsp was not affected by any of the treatments, and the course of Texp/Tinsp 198 
over time did not differ among treatments. The mean baseline value before treatment was 1 ± 199 
0.24. Irrespective of the respiratory stimulant, the lowest value was 0.97 ± 0.19 measured 5 min 200 
after treatment and the highest 1.01 ± 0.30 after 30 min. 201 
 202 
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Blood gas analysis 203 
Over the 90 min recording period, there were significant differences among the three 204 
treatments with respect to PaO2 (Fig. 3a). Doxapram led to a significant increase in PaO2 from 205 
77.7 ± 18.9 mmHg to a maximum value of 93.2 ± 23.7 mmHg at 1 min. Prethcamide caused a 206 
significant increase in PaO2 at 90 min compared with values before and 1, 5, 15 and 30 min after 207 
treatment (all P < 0.01). Lobeline did not affect PaO2. 208 
 209 
There were significant differences among the three treatments with respect to PaCO2 (P < 210 
0.0001). Doxapram caused a significant decrease in PaCO2 from a baseline value of 42.6 ± 4.9 211 
mmHg to 33.1 ± 6.6 mmHg at 1 min, and the measurements remained decreased throughout the 212 
study period (Fig. 3b). Prethcamide caused a significant gradual decrease in PaCO2 from the 213 
baseline value of 42.0 ± 4.9 mmHg to a minimum of 38.5 ± 6.4 mmHg at 30 min (P ≤ 0.05). 214 
Lobeline did not affect PaCO2. 215 
 216 
The sO2 profiles of arterial blood did not differ among treatments. Doxapram caused a 217 
transient increase in sO2 from a baseline value of 91 ± 10 % - 95 ± 7 % at 1 min (P < 0.01).  218 
 219 
Acid base variables 220 
Doxapram, but not prethcamide and lobeline, significantly affected arterial pH, 221 
bicarbonate concentration and BE. Doxapram caused a significant increase in arterial pH from a 222 
baseline value of 7.45 ± 0.06 - 7.51 ± 0.05 at 1 min (Fig. 3c; P < 0.0001). Bicarbonate 223 
concentration decreased after doxapram from a baseline value of 28.2 ± 4.1 mmol/L and reached 224 
a minimum of 25.2 ± 4.1 mmol/L at 5 min (P ≤ 0.05). Base excess in arterial blood decreased 225 
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from a baseline value of 4.3 ± 2.9 mmol/L and reached a minimum of 2.4 ± 4.5 mmol/L at 5 min 226 
(P ≤ 0.05).  227 
 228 
 In venous blood, only pH was affected by treatment. During the entire post-treatment 229 
study period, the venous pH was higher after treatment with doxapram than after treatment with 230 
prethcamide and lobeline (P < 0.001). 231 
 232 
Discussion 233 
Disturbances in respiratory adaption to extra-uterine life are a major cause of perinatal 234 
mortality in calves (Eigenmann, 1981; Szenci, 2003). A variety of physical and pharmacological 235 
measures are commonly used in an attempt to correct these disturbances immediately after 236 
calving (Winnie, 1973; Szenci, 1986; Uystepruyst et al., 2002). Physical measures, including the 237 
use of a suction pump to remove fluid from the pharynx and nose, pouring cold water into the 238 
ears and over the head and warming the calf using an infrared radiant heater, only had minor 239 
effects on arterial blood gas and respiratory variables in newborn Belgian white blue calves that 240 
did not have asphyxia. However, pharyngeal and nasal suctioning reduced the pCO2 and warming 241 
the calves increased arterial sO2, and both measures changed the breathing pattern to deeper and 242 
slower breathing compared with non-treated controls (Uystepruyst et al., 2002). In the current 243 
study, doxapram caused distinct changes in respiratory variables in healthy 3 - 15 h old neonatal 244 
calves, leading to a significant increase in mean minute volume by 106% within 1 min after 245 
treatment. Mean minute volume before treatment was similar to published values (Varga et al., 246 
1999). In lambs, doxapram (2.5 mg/kg BW) increased the Vmin by 54% (Bairam et al., 1990). 247 
Similarly, doxapram (loading dose of 0.5 mg/kg, followed by a 20-min infusion at 0.03 248 
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mg/kg/min and then 0.08 mg/kg/min) caused increases in RR and Vmin by more than 100% in 249 
anaesthetised 1- 3 day-old foals with induced hypercapnia, (Giguere et al., 2007). 250 
 251 
The distinct rise in the minute volume in our study was more likely induced by an 252 
increase in peak inspiratory and expiratory flows than by an increase in RR, because RR rose 253 
only by 52%, whereas PIF and PEF increased by 102% and 86%. This was in agreement with a 254 
previous study involving 2 - 6 h old calves without asphyxia in which doxapram caused a similar 255 
increase in RR from a mean of 56 - 106 breath/min (Bleul et al., 2010). The results of the current 256 
study therefore demonstrated that doxapram (40 mg IV) had a noticeable effect on ventilation, 257 
reflected by an increase in the amount of air that is inhaled and exhaled by the calf, which in turn 258 
increased pulmonary gas exchange (a transient increase in PaO2 and a distinct decrease in PaCO2 259 
within 1 min of doxapram administration). 260 
 261 
These improvements in pulmonary gas exchange and the rapid (within 30 s) increase in 262 
pH (7.37 ± 0.04 - 7.53 ± 0.07) have been reported previously (Bleul et al., 2010). The marked 263 
increase in mean minute volume after the doxapram treatment could have induced 264 
hyperventilatory hypocapnia (PaCO2 < 35 mmHg), which may have resulted in a rise in pH to the 265 
alkalotic range. A low PaCO2 causes a shift in the carbonic-acid-bicarbonate equilibrium toward 266 
CO2 and H2O production (Meyfeldt, 2004), which is associated with decreasing bicarbonate 267 
concentration and decreasing BE, consistent with the current study, for at least 15 min. 268 
Hypocapnia has been associated with cerebral vasoconstriction, which in turn can lead to cerebral 269 
hypoxia (Funderburk et al., 1968). However, the calves in the current study did not present any 270 
clinical signs of depression or neurological disorders. Furthermore, asphyxic neonatal calves have 271 
a PaCO2 that is approximately twice as high as the pressures measured in calves without asphyxia 272 
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in the current study, which would make a decrease in the PaCO2 into the hypocapnic range in 273 
response to doxapram treatment unlikely. Acidotic neonatal calves delivered by caesarean section 274 
and treated with doxapram immediately after birth had a decrease in PvCO2 (Szenci, 1986) that 275 
was lower than in untreated controls (Herfen, 1997). In both of these studies, hypocapnia did not 276 
occur, but the PvCO2 remained above 45 mmHg in the hypercapnic range. However, these studies 277 
used venous blood, where the PvCO2 is determined primarily by the bicarbonate in the periphery.  278 
 279 
Published reports on the efficacy of prethcamide for the establishment of a normal 280 
breathing pattern in newborn calves are equivocal. In one study, prethcamide had no effect in 281 
neonatal calves, with or without asphyxia, as determined by venous blood gas analysis and 282 
clinical examination (Herfen, 1997). In another study in non-acidotic calves delivered by 283 
caesarean section, prethcamide significantly reduced pH and 10-60 min post-partum, compared to 284 
untreated controls (Szenci, 1986). In contrast, prethcamide induced significant increases in PaO2 285 
and decreases in PaCO2 changes in arterial blood that indicated improvement in ventilation in the 286 
current study, possibly due to larger tidal volumes (Vin and Vexp), as has been reported in humans 287 
(Sams et al., 1997). However, prethcamide had no effect on minute volume and we were unable 288 
to explain the relationship between the increasing tidal volumes immediately after prethcamide 289 
administration and the changes in PaCO2 seen 30 min and in PaO2 90 min post treatment.  290 
 291 
Pharmacokinetic studies have shown that the maximum concentration of prethcamide in 292 
blood is reached 3 min after oral administration and has decreased by 66% by 60 min 293 
(Anonymous, 1998). In the current study, the stimulatory effect of oral prethcamide on 294 
respiration was generally minimal and improvements in blood gas variables were greatly delayed, 295 
so this drug may not be useful to treat acute asphyxia. However, it is possible that the positive 296 
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effect of prethcamide is more pronounced in animals with a very high PaCO2, although the effect 297 
of prethcamide is believed to be independent of PaCO2, except for specific limits (Anderton and 298 
Harris, 1963). 299 
 300 
Surprisingly, both spirometric measurements and blood gas analysis failed to show a 301 
positive effect of IV of lobeline on ventilation. There have been several studies in human and 302 
veterinary medicine that showed an increase in RR and tidal volume after the administration of 303 
lobeline (Winnie, 1973; Herholz et al., 2001). In Holstein and Belgian blue calves with a mean 304 
BW of 143 ± 20 kg, an increase in both variables occurred, which in turn was associated with a 305 
rise in Vmin (Bureau et al., 1999a). Possible reasons why lobeline failed to have an effect were the 306 
dose used and the age of the calves. We used the 5 mL dose (5 mg) recommended by the 307 
manufacturer for calves with a mean BW of 45 kg (~ 0.11 mg/kg BW), while another study used 308 
four different doses of lobeline ranging from 0.05 - 0.35 mg/kg BW IV (Bureau et al., 1999a). 309 
When lobeline was used at a dose similar to the one in the current study (0.15 mg/kg BW), there 310 
were significant increases in RR, tidal volume and minute volume, compared with baseline 311 
values and values elicited by lower doses. It was therefore more likely that the lack of effect of 312 
lobeline was age rather than dose related, particularly when considering lobeline was less 313 
effective in 10 day-old foals (Marlin et al., 1997) and calves less than 2 weeks old (Bureau et al., 314 
1999b), compared to mature animals.  315 
 316 
Any age-related difference may be due to a lower responsiveness of the neonatal 317 
respiratory centre to stimulant drugs, since the sensitivity to oxygen rises during the postnatal 318 
period in rats (Eden and Hanson, 1987). A critical factor in the current study was the very short 319 
duration of action of lobeline. In previous studies, RR reached a maximum 5 s after 320 
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administration of the drug, tidal and minute volumes were maximal after 30 s and had declined 321 
considerably by 1 min (Bureau et al., 1999a). It is therefore possible that the maximum values for 322 
respiratory rate and tidal and minute volumes were missed in the current study since the first 323 
measurement was recorded 1 min after treatment, although we would have expected that lobeline 324 
would have led to some detectable effect in the blood after 1 min. Newborn non-acidotic calves 325 
showed a decrease in venous pH, BE and HCO3
-
 10 min after birth (Szenci, 1986). Our results 326 
indicated that lobeline at the recommended dose does not significantly stimulate ventilation and 327 
does not improve pulmonary gas exchange in neonatal calves up to 24 h old. Further spirometric 328 
studies are needed to determine whether higher doses might have a beneficial effect in newborn 329 
calves. 330 
 331 
Conclusions 332 
Only doxapram had a distinct stimulatory effect on ventilation in healthy newborn calves, 333 
while prethcamide and lobeline did not. Doxapram caused noticeable changes in blood gas and 334 
acid base variables, which included a decrease in PaCO2 and increase in PaO2. These specific 335 
effects of doxapram should theoretically be of great benefit in the treatment of neonatal asphyxia 336 
because they shorten the postnatal hypoxic phase and duration of respiratory acidosis. Whether 337 
these effects do in fact occur when asphyxic calves are treated immediately after birth need to be 338 
investigated in future studies. 339 
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Figure legends 517 
Fig. 1. Calf with spirometry equipment held in place by operator during the measurements. (A) 518 
mask; (B) spirette; (*) position of ultrasound transducers. 519 
 520 
Fig. 2. (a) Respiratory rate (RR), (b) maximum inspiratory flow  (PIF) and (c) minute volume 521 
(Vmin) in 18 calves before and after administration of doxapram (♦), prethcamide (■) and lobeline 522 
(▲). (↑) indicates times of treatment and (*) indicates time points with values significant 523 
different to baseline after doxapram treatment. 524 
 525 
Fig. 3. PaO2 (a), PaCO2 (b) and arterial pH (c) in 18 calves before and after the administration of 526 
doxapram (♦), prethcamide (■) and lobeline (▲).(↑) indicates times of treatment, (*) indicates 527 
time points with values significant different to baseline after doxapram treatment and (+) 528 
indicates time points with values significant different to baseline after prethcamide treatment. 529 
 530 
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